This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT00889473 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | 9 Meters Biopharma, Inc. |
| Enrollment | 42 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Celiac Disease |
| Interventions | Larazotide acetate; Placebo; Gluten 900 mg |
| Start | Apr 2009 |
| Primary completion | Nov 2009 |
| Study completion | Apr 2010 |
| Results posted | Not yet |
| Registry last updated | Sep 20, 2017 |
Compounds on this site that cite this trial
What the registry says the trial is about
This study is designed to evaluate the efficacy of a single dose of larazotide acetate in preventing intestinal permeability changes induced by a 6-week gluten challenge in subjects with celiac disease
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Response to gluten | 6 weeks |
1 secondary outcome also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
